Is there a non-invasive ovarian teratoma

summary

Ovarian teratoma is one of the main causes of female infertility, which also affects the problem of feeding the next generation. We should pay attention to it. In many years of medical practice, we often encounter patients with ovarian teratoma, so is there a non-invasive ovarian teratoma? Next, I'll talk about my experience.

Is there a non-invasive ovarian teratoma

First, teratomas originated from potential pluripotent primordial embryo cells, most of which were benign, but the malignant tendency increased with age. Most of them were found in sacrococcygeal region, mediastinum, retroperitoneum and gonad. Most of them occurred in newborns and infants, especially in women. 　

Second: once teratoma is diagnosed, early surgical resection must be made to avoid malignant transformation of benign teratoma caused by delayed operation, and prevent infection, rupture, bleeding and complications of tumor. The key point of operation for teratoma is to remove the tumor completely. For ovarian and testicular tumors, one side of the ovary or testis should be removed. For sacrococcygeal teratoma, it is emphasized that the tailbone should be removed at the same time, so as to avoid residual pluripotent cells leading to tumor recurrence.

Third: the treatment principle of malignant teratoma is combined with adjuvant therapy. After surgical resection, conventional chemotherapy is used for 1.5-2 years. Radiotherapy is only used to confirm the cases of malignant teratoma with microscopic or macroscopic residual. The dosage of radiotherapy is 25Gy for microscopic residual, and 35gy for macroscopic residual. In recent years, chemotherapy is advocated for patients with complete surgical resection, and radiotherapy should be used cautiously to avoid radiotherapy Delayed damage of reproductive organs and bone development.

matters needing attention

Generally speaking, the lower the incidence of malignant teratomas found at childbearing age. At present, the survival rate of comprehensive treatment after complete resection of malignant ovarian teratoma can reach 97%, and the survival rate of residual or recurrent patients can be improved.